Policosanol is a natural mixture of long-chain primary alcohols (C24-C34) primarily derived from sugarcane wax (Saccharum officinarum L.). It is clinically used as a lipid-lowering agent, functioning primarily by inhibiting hepatic cholesterol synthesis via HMG-CoA reductase regulation. Its efficacy and safety profile are distinct from synthetic statins, making it a consideration in specific patient populations in India, particularly those with statin intolerance or seeking nutraceutical options.
Adult: 10mg to 20mg once daily, typically in the evening. The 20mg dose is common for therapeutic lipid-lowering effects. Initiation at 10mg/day for 4-8 weeks, with titration to 20mg based on lipid profile response.
Note: Administer orally, preferably with the evening meal to coincide with the body's peak cholesterol synthesis period and to enhance absorption with dietary fats. Tablet/Capsule should be swallowed whole with a glass of water. Do not crush or chew.
Policosanol's primary mechanism involves the inhibition of cholesterol biosynthesis in the liver. It does not directly inhibit HMG-CoA reductase but regulates its activity, leading to a decrease in the synthesis of mevalonic acid, a cholesterol precursor. This upregulation of LDL receptor activity enhances the clearance of LDL-cholesterol from the bloodstream. It may also inhibit platelet aggregation and have antioxidant properties.
Pregnancy: Category N (Not classified by US FDA). Contraindicated. Animal reproduction studies are insufficient. Risk of disrupting fetal cholesterol synthesis, which is crucial for development.
Driving: May cause dizziness. Patients should be cautioned about driving or operating machinery if they experience dizziness.
| Warfarin, Acenocoumarol | Increased risk of bleeding due to additive antiplatelet effect. May potentiate INR. | Major |
| Aspirin, Clopidogrel, NSAIDs (e.g., Ibuprofen, Diclofenac) | Additive antiplatelet effect, increasing bleeding risk. | Moderate to Major |
| Simvastatin, Atorvastatin, other Statins | Theoretical additive cholesterol-lowering effect; increased risk of myopathy not well-established but monitor. | Moderate |
| Cyclosporine, Gemfibrozil | Potential increased risk of myalgia or hepatotoxicity. | Moderate |
Same composition (Policosanol (20mg)), different brands: